Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

European regulatory issues

J Betts1

  • 1Alpha Therapeutic UK Ltd, Thetford, Norfolk.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

European Union regulations for blood products need improvement. New legislation establishes the European Medicines Evaluation Agency but comprehensive rules for plasma collection, virus screening, and batch release are still required.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and cost-effectiveness of admissions to women's crisis houses compared with traditional psychiatric wards: pilot patient-preference randomised controlled trial.

The British journal of psychiatry. Supplement·2010
Same author

Gastrointestinal tract involvement associated with the 3243A>G mitochondrial DNA mutation.

Neurology·2008
Same author

Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement.

Neuropathology and applied neurobiology·2006
Same author

Mitochondrial DNA damage in non-melanoma skin cancer.

British journal of cancer·2003
Same author

Using honey dressings: the practical considerations.

Nursing times·2002
Same author

Growth phase-associated changes in protein expression in Mycobacterium smegmatis identify a new low molecular weight heat shock protein.

Tuberculosis (Edinburgh, Scotland)·2001
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Area of Science:

  • Pharmaceutical Regulation
  • Biologics Manufacturing
  • Public Health Policy

Background:

  • Current European Union (EU) regulations exhibit gaps in addressing the complete manufacturing and control processes for blood products.
  • Recent legislative changes, effective January 1, 1995, established the European Medicines Evaluation Agency (EMEA).
  • Revised pharmaceutical product approval systems are in place, impacting blood product oversight.

Purpose of the Study:

  • To identify deficiencies in existing EU regulations concerning blood product manufacture and control.
  • To highlight the need for harmonized legislation in specific critical areas.
  • To inform regulatory bodies and stakeholders about necessary improvements.

Main Methods:

  • Analysis of current EU legislation pertaining to blood products.

Related Experiment Videos

  • Review of recent regulatory changes and the establishment of the EMEA.
  • Identification of areas lacking comprehensive regulatory coverage.

    • Main Results:

    • Existing EU regulations do not fully encompass all facets of blood product manufacturing and control.
    • The establishment of the EMEA and revised approval systems represent progress but do not address all identified gaps.
    • Specific areas requiring harmonized legislation include plasma collection and screening, virus validation studies, and batch release.

    Conclusions:

    • Comprehensive and harmonized EU legislation is essential for the safe and effective manufacture and control of blood products.
    • Addressing plasma collection, screening, virus validation, and batch release is critical for regulatory completeness.
    • Further regulatory development is needed to ensure robust oversight of the blood product supply chain.